Researchers from the Mayo Clinic and Arizona State University’s Biodesign Institute have collaborated to identify biological markers in the blood of patients with Crohn’s disease, spurring optimism that a simple blood test could be developed to accurately diagnose the disease.
Researchers from the Mayo Clinic and Arizona State University’s Biodesign Institute have collaborated to identify biological markers in the blood of patients with Crohn’s disease, spurring optimism that a simple blood test could be developed to accurately diagnose the disease.
The Biodesign Institute works to discover biomarkers that can help clinicians assess patients’ risk of serious illnesses like cancer, diabetes, and Crohn’s disease. This last condition, which is the most commonly occurring inflammatory bowel disease, presents a particular challenge to researchers, physicians, and patients alike due to its undetermined biological pathways. Crohn’s disease is a chronic and painful condition that occurs when the body’s immune system attacks its own gut.
In a press release, the lead authors of the biomarker study explained that the current arduous process of diagnosing Crohn’s disease through scans and biopsies presents a significant obstacle for patients enduring the disease’s gastrointestinal symptoms. However, if a simple blood test could identify signs of Crohn’s, patients may be able to begin treatment sooner, while researchers would learn more about the mechanisms of the disease.
“If we are going to truly alter the natural history of Crohn’s disease and help people, we needed to develop a new test for early, accurate diagnosis, as well as administrating appropriate therapy,” said study author Josh LaBaer, MD, PhD, interim executive director of the Biodesign Institute.
According to Ji Qiu, PhD, also of the Biodesign Institute, the research team hypothesized that the disease might be linked to immune biomarkers that could someday be detected through commercial blood tests.
“There has been increasing evidence that suggests the Crohn’s disease immune response may be a result of altered microbes in the gut or exposure to harmful toxins that will result in antibodies against microbial and human proteins being made that are very specific manifestation of the disease,” Qiu said.
After examining serum samples collected by the Mayo Clinic from 48 Crohn’s patients, the researchers flagged several possible immune biomarkers, or autoantibodies, then conducted tests on protein arrays to assess the sensitivity and specificity of each. They found that bacterial flagellin antibodies were the strongest biomarker indicators, but also identified a novel biomarker, the antibody against small nuclear ribonucleoprotein-associated protein B.
“One possibility is that these antibodies reflect dysregulated immune response in the gut,” explained LaBaer. “Another is that they could play a pathogenic role. But so far, we simply don’t have enough such antibodies discovered to understand their functional role.”
The study authors acknowledged that further research would be needed to examine the relationships between Crohn’s and thousands of proteins and antibodies. They also stated that a panel of biomarkers, not just one on its own, would be the most powerful tool for clinical diagnosis. Still, they wrote, this study represented a cause for hope that Crohn’s could someday be easier to spot through a simple blood test.
“We are excited about the potential of this immunoproteomics approach for Crohn’s disease and will work to discover additional biomarkers,” LaBaer concluded.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More